JAC-AMR
Curious to know more about the #Netflix model for antimicrobials? The SMASH study in the UK explored the views of infection consultants in England on the novel antimicrobial subscription model for #cefiderocol and #ceftazidime-avibactam that started in July 2022. Are delinked funding models the solution to the dry antimicrobial production pipeline?
https://doi.org/10.1093/jacamr/dlad091
#JACAMRNews
Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study

AbstractObjectives. A novel ‘subscription-type’ funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the vi

OUP Academic
Aug 22, 2023 at 10:14amWeb
Show threadGabriele PollaraAug 22, 2023

@JACAMR this is an important study looking at how we introduce into the market new #antibiotics against #AMR and provide enough incentive to develop and use them, both for drug companies and hospital #doctors

Recommended 👆 #MedMastodon #IDMastodon #infectiousdiseases #medicine #infection #microbiology @infectiousdiseases @MicrobioJC @microbiology